Tyra Biosciences’ (TYRA) “Outperform” Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of Tyra Biosciences (NASDAQ:TYRA) in a research note issued to investors on Thursday morning,Benzinga reports. Wedbush currently has a $53.00 price objective on the stock.

Other equities research analysts have also issued reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tyra Biosciences in a report on Friday, July 17th. Jefferies Financial Group reiterated a “buy” rating and issued a $42.00 price objective on shares of Tyra Biosciences in a report on Wednesday, August 5th. Bank of America boosted their price objective on shares of Tyra Biosciences from $37.00 to $42.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. Wolfe Research initiated coverage on shares of Tyra Biosciences in a research report on Tuesday, May 19th. They issued a “peer perform” rating for the company. Finally, JonesTrading assumed coverage on Tyra Biosciences in a research note on Wednesday, June 17th. They set a “buy” rating and a $56.00 target price for the company. Eleven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $47.88.

Tyra Biosciences Stock Performance

Shares of NASDAQ:TYRA opened at $22.03 on Thursday. The business’s 50-day simple moving average is $28.39 and its 200 day simple moving average is $31.84. The company has a market cap of $1.31 billion, a P/E ratio of -9.18 and a beta of 0.73. Tyra Biosciences has a one year low of $11.82 and a one year high of $40.65.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.04). Analysts predict that Tyra Biosciences will post -2.74 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Hilton Head Capital Partners LLC bought a new stake in shares of Tyra Biosciences in the 1st quarter worth about $30,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Tyra Biosciences during the fourth quarter worth about $51,000. State of Wyoming bought a new position in shares of Tyra Biosciences during the second quarter worth about $76,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Tyra Biosciences by 14.5% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock worth $126,000 after purchasing an additional 1,668 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its stake in Tyra Biosciences by 27.7% in the third quarter. Russell Investments Group Ltd. now owns 12,741 shares of the company’s stock worth $178,000 after purchasing an additional 2,766 shares in the last quarter. 84.14% of the stock is currently owned by institutional investors.

Tyra Biosciences News Summary

Here are the key news stories impacting Tyra Biosciences this week:

• Positive Sentiment: Initial SURF302 results support further development of dabogratinib in bladder cancer, providing evidence of potential activity for Tyra’s lead program. The Pharma Letter article
• Positive Sentiment: Wedbush reaffirmed its “Outperform” rating and maintained a $53 price target, signaling substantial potential upside if the clinical program succeeds. Benzinga analyst rating report
• Positive Sentiment: Director Rehan Verjee purchased 972 shares for approximately $20,004 at an average price of $20.58. The insider purchase may be viewed as a signal of confidence, although its size is modest relative to the company’s market value. SEC insider ownership filing
• Neutral Sentiment: Reported short-interest data showed zero shares sold short and a zero-day short-interest ratio, but the figures appear anomalous and provide little useful information about trading sentiment.
• Negative Sentiment: Coverage indicated that bladder-cancer response rates from SURF302 were below investor expectations, creating uncertainty about dabogratinib’s commercial and regulatory potential. BioSpace article
• Negative Sentiment: HC Wainwright lowered its price target from $45 to $30, although it retained a “Buy” rating, reflecting reduced near-term expectations following the trial update. Benzinga analyst rating report
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of TYRA investors, adding a legal and reputational overhang. The announcement did not establish wrongdoing by Tyra. Pomerantz investor alert

About Tyra Biosciences

Tyra Biosciences, Inc is a clinical-stage biotechnology company focused on developing precision medicines for diseases with limited treatment options. The company uses its proprietary SNÅP platform to design small-molecule therapies intended to selectively target disease-driving genetic alterations while addressing resistance mechanisms that can reduce the effectiveness of existing treatments.

Tyra’s lead programs are directed at fibroblast growth factor receptor (FGFR) biology. TYRA-300 is an oral, selective FGFR3 inhibitor being developed for conditions including FGFR3-altered urothelial cancer and achondroplasia, a genetic skeletal disorder.